Vaxcyte, Inc. PCVX Investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept pcvx:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAnd12MonthsOrLonger.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer?
- Vaxcyte, Inc. (PCVX) reported investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer of $4.9M in Q1 2026.
- How has Vaxcyte, Inc.'s investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer changed year-over-year?
- Vaxcyte, Inc.'s investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer increased by 53.1% year-over-year, from $3.2M to $4.9M.